Detalles de la búsqueda
1.
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma.
Eur Urol Focus;
2024 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38839505
2.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol;
25(5): 563-571, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38621400
3.
Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial.
Eur Urol Oncol;
2024 Apr 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38582650
4.
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Lancet Oncol;
25(1): 99-107, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38043558
5.
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma.
BJU Int;
133 Suppl 3: 57-67, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37986556
6.
NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma.
Neurooncol Adv;
5(1): vdad124, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37841696
7.
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
Lancet Oncol;
24(8): 881-891, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37451291
8.
Targeting XBP1 mRNA splicing sensitizes glioblastoma to chemotherapy.
FASEB Bioadv;
5(5): 211-220, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37151848
9.
The Membrane Protein Sortilin Is a Potential Biomarker and Target for Glioblastoma.
Cancers (Basel);
15(9)2023 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-37173980
10.
Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT).
Ther Adv Med Oncol;
15: 17588359231156392, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36872949
11.
ProNGF Expression and Targeting in Glioblastoma Multiforme.
Int J Mol Sci;
24(2)2023 Jan 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-36675126
12.
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.
Neuro Oncol;
25(2): 339-350, 2023 02 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35849035
13.
Chemoradiotherapy with concurrent durvalumab for the palliative treatment of oligometastatic oesophageal and gastrooesophageal carcinoma with dysphagia: a single arm phase II clinical trial (PALEO, sponsored by the Australasian Gastro-Intestinal Trials Group).
BMC Cancer;
22(1): 1324, 2022 Dec 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-36528772
14.
Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma.
BMJ Open;
12(9): e058107, 2022 09 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36104135
15.
Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.
Eur J Cancer;
170: 73-84, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35598359
16.
What matters for people with brain cancer? Selecting clinical quality indicators for an Australian Brain Cancer Registry.
Neurooncol Pract;
9(1): 68-78, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35096405
17.
Find the path of least resistance: Adaptive therapy to delay treatment failure and improve outcomes.
Biochim Biophys Acta Rev Cancer;
1877(2): 188681, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35051527
18.
Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib).
Clin Cancer Res;
28(8): 1518-1530, 2022 04 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35091440
19.
Identifying the unmet supportive care needs of people affected by kidney cancer: a systematic review.
J Cancer Surviv;
16(6): 1279-1295, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34595697
20.
177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial.
J Nucl Med;
63(4): 560-566, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34326127